Clearmind Medicine Inc. (CMND)

CA — Healthcare Sector

Peers: HILS COEP MGTA QNRX CDIO WINT NBY BXRX REVB BWV PXMD UNCY VRAX IMMX CNSP EFTR NAVB SONN

Automate Your Wheel Strategy on CMND

With Tiblio's Option Bot, you can configure your own wheel strategy including CMND - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol CMND
Rev/Share 0.0
Book/Share 0.457
PB 1.929
Debt/Equity 0.0156
CurrentRatio 1.7446
ROIC -2.6153

MktCap 4742514.0
FreeCF/Share -0.9087
PFCF -1.0364
PE -0.9183
Debt/Assets 0.0069
DivYield 0
ROE -1.6477

Rating C+
Score 2
Recommendation Sell
P/E Score 1
DCF Score 4
P/B Score 3
D/E Score 3

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
No ratings available.

News

Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market

CMND
Published: June 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

Vancouver, Canada, June 27, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the addition of Hadassah-University Medical Center, Jerusalem, Israel, as a new clinical site for its ongoing Phase I/IIa clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD).

image for news Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market

Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder

CMND
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral

Vancouver, Canada, June 23, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the addition of Tel Aviv Sourasky Medical Center (TASMC), Tel Aviv, Israel, as an additional clinical site for its ongoing Phase I/IIa clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). This expansion follows the recent enrollment of the first patient in the trial, announced on June 5, 2025, marking a …

image for news Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics

CMND
Published: June 12, 2025 by: GlobeNewsWire
Sentiment: Neutral

Vancouver, Canada, June 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics

image for news Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics

Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment

CMND
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral

CMND-100 has the potential to provide an innovative and advanced treatment option for hundreds of millions of people around the world afflicted with Alcohol Use Disorder

image for news Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment

Clearmind Medicine's FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones

CMND
Published: March 21, 2025 by: GlobeNewsWire
Sentiment: Neutral

Vancouver, Canada, March 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today that its innovative drug candidate, CMND-100, has arrived in the United States following successful manufacturing. This marks a key milestone as the Company prepares to initiate its FDA-approved Phase I/IIa clinical trial for the treatment of Alcohol Use Disorder (AUD), a condition affecting over 28 million adults in the U.S. alone.

image for news Clearmind Medicine's FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones

About Clearmind Medicine Inc. (CMND)

IPO Date 2022-11-15
Website https://www.clearmindmedicine.com
Industry Biotechnology
CEO Adi Zuloff-Shani
Employees 4

Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.